Abstracts tagged "anti-CCP antibodies"

Abstract Number: 1033 • 2017 ACR/ARHP Annual Meeting
Burden of Illness in Patients with RA and Anti-Cyclic Citrullinated Peptide Positivity
ML Paudel¹, JP Swindle¹, J McPheeters¹, R Szymialis² and K Price², ¹Optum, Inc., Eden Prairie, MN, ²Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: RA is often treated with a biologic DMARD (bDMARD), such as abatacept (ABA) or a TNF inhibitor (TNFi). Real-world data on how economic outcomes…
Abstract Number: 1034 • 2017 ACR/ARHP Annual Meeting
Presence of Anti-Cyclic Citrullinated Peptide Antibodies Is Associated with Better Treatment Response to Abatacept but Not to TNF Inhibitors in Patients with RA: A Meta-Analysis
E Alemao¹, R Postema², Y Elbez³, C Mamane⁴ and Axel Finckh⁵, ¹Bristol-Myers Squibb, Princeton, NJ, ²Bristol-Myers Squibb, Uxbridge, United Kingdom, ³Excelya, Boulogne-Billancourt, France, ⁴Mapi, London, United Kingdom, ⁵University Hospital of Geneva, Geneva, Switzerland
Background/Purpose: The association between anti-citrullinated protein antibody (ACPA) status and erosions, as well as response to TNF inhibitor (TNFi) treatment, has been explored.1,2 Results based…
Abstract Number: 1402 • 2017 ACR/ARHP Annual Meeting
In RA, Becoming Seronegative over the 1st Year of DMARD Treatment Does Not Improve Chances of Drug-Free Remission in the Long-Term
Emma de Moel¹, Veerle Derksen¹, LA Trouw¹, Holger Bang², Yvonne P. Goekoop-Ruiterman³, GM Steup-Beekman^1,4, Tom W.J. Huizinga⁵, Cornelia F Allaart⁵, Rene E.M. Toes¹ and Diane van der Woude⁶, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Orgentec Diagnostika GmbH, Mainz, Germany, ³Rheumatology, HAGA hospital, The Hague, Netherlands, ⁴Rheumatology, Haaglanden Medical Center, The Hague, Netherlands, ⁵Department of Rheumatology, LUMC, Leiden, Netherlands, Leiden, Netherlands, ⁶Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Patients with RA harbor autoantibodies of various isotypes and directed against several post-translational modifications. Baseline seropositivity is a poor prognostic factor for sustained drug-free…
Abstract Number: 2914 • 2017 ACR/ARHP Annual Meeting
Anti-CCP Antibody Levels Are Elevated in Cervicovaginal Fluid in Association with Local Inflammation in Premenopausal Women without RA
Sonia Khatter¹, Heather Berens-Norman², Courtney Anderson¹, Justin August¹, Marie L. Feser¹, Chelsie Fleischer¹, Ashley Visser¹, Jill M. Norris³, V. Michael Holers¹, Kevin D. Deane¹ and M. Kristen Demoruelle¹, ¹Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, ²University of Colorado School of Medicine, Aurora, CO, ³Department of Epidemiology, Colorado School of Public Health, Aurora, CO
Background/Purpose: Data support that anti-CCP antibodies likely originate at a mucosal site prior to the onset of inflammatory arthritis (IA) in the development of RA.…
Abstract Number: 2916 • 2017 ACR/ARHP Annual Meeting
The Presence of a Large Number of Autoantibodies at Baseline Is Favourable for Early Treatment Response but Unfavourable for Drug-Free Remission in RA Patients
Emma de Moel¹, Veerle Derksen¹, LA Trouw¹, Holger Bang², R.J. Goekoop³, I Speyer⁴, TWJ Huizinga¹, CF Allaart¹, REM Toes¹ and Diane van der Woude⁵, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Orgentec Diagnostika GmbH, Mainz, Germany, ³Haga Hospital, The Hague, Netherlands, ⁴Haaglanden Medical Center, The Hague, Netherlands, ⁵Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: The autoantibody response of seropositive RA is very diverse and consists of various numbers of isotypes and antibodies to multiple post-translational modifications. It is…
Abstract Number: 239 • 2017 ACR/ARHP Annual Meeting
Ultrasound Abnormalities Predict Arthritis Development in ACPA and/or RF Positive Arthralgia Patients
Annelies Blanken¹, Marian van Beers-Tas¹, Marlies Meursinge Reynders¹ and Dirkjan van Schaardenburg^1,2, ¹Amsterdam Rheumatology and immunology Center | Reade, Amsterdam, Netherlands, ²Amsterdam Rheumatology and immunology Center | Academic Medical Center, Amsterdam, Netherlands
Background/Purpose: Early diagnosis of rheumatoid arthritis (RA) is important for controlling disease activity and preventing joint damage. Individuals positive for anticitrullinated protein antibodies (ACPA) and/or…
Abstract Number: 476 • 2017 ACR/ARHP Annual Meeting
Novel Interaction between Anti-Citrulline Monoclonal Antibodies and Apoptotic Cells Is Mediated through Citrullinated Nuclear Antigens
Katy A. Lloyd¹, Peter Sahlström², Johanna Steen¹, Philip J. Titcombe^3,4, Diana Zhou¹, Christina Lundqvist⁵, Olov Ekwall^6,7, Jimmy Ytterberg¹, Johan Rönnelid⁸, Daniel L. Mueller³, Lars Klareskog¹, Vivianne Malmström¹ and Caroline Grönwall⁹, ¹Dept. of Medicine, Rheumatology Unit, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ²Dept. of Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden, ³Dept. of Medicine, University of Minnesota Medical School, Minneapolis, MN, ⁴Dept. of Medicine, Rheumatology Unit, Karolinska Institutet, Karolinska University Hospital, Sweden, Sweden, ⁵Dept. of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Göteborg, Sweden, ⁶Dept. of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy University of Gothenburg, Göteborg, Sweden, ⁷Dept of Pediatrics, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Göteborg, Sweden, ⁸Department of Immunology Genetics and Pathology, Uppsala University, Uppsala, Sweden, ⁹Dep. of Medicine, Rheumatology Unit, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
Background/Purpose: Anti-citrullinated protein antibodies (ACPA) display broad cross-reactivities and target proteins including a-enolase, filaggrin, vimentin, fibrinogen, and histones. However, every monoclonal ACPA has a distinct…
Abstract Number: 477 • 2017 ACR/ARHP Annual Meeting
Monoclonal ACPA-IgG Feature Extensive Fab Glycosylation
Katy A. Lloyd¹, Johanna Steen¹, Philip J. Titcombe^2,3, Khaled Amara⁴, Diana Zhou¹, Lena Israelsson⁵, Susanna L. Lundström⁶, Daniel L. Mueller³, Lars Klareskog¹, Vivianne Malmström¹ and Caroline Grönwall⁷, ¹Dept. of Medicine, Rheumatology Unit, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ²Dept. of Medicine, Rheumatology Unit, Karolinska Institutet, Karolinska University Hospital, Sweden, Sweden, ³Dept. of Medicine, University of Minnesota Medical School, Minneapolis, MN, ⁴Department of Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden, ⁵Dept. of Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden, ⁶Dept. of Medical Biochemistry and Biophysics, Division of Physiological Chemistry, Karolinska Institutet, Stockholm, Sweden, ⁷Dep. of Medicine, Rheumatology Unit, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
Background/Purpose: Fab-glycosylation is found in ~15-25% serum IgG and while its exact consequence remains unknown, it may alter IgG functionality. Recent data revealed elevated Fab-glycosylation…
Abstract Number: 481 • 2017 ACR/ARHP Annual Meeting
Immunocompetent Cells Expressing Citrullinated Proteins in Joint Synovium of Osteoarthritis and Rheumatoid Arthritis
Kyoko Honne¹, Masahiro Iwamoto², Shunichiro Hanai¹, Satoshi Machida³, Hitoshi Sekiya⁴, Reina Tsuda⁵, Tatsuhiko Ozawa⁵, Tadayoshi Karasawa⁶, Atsushi Muraguchi⁵, Masafumi Takahashi⁶, Hiroyuki Kishi⁵ and Seiji Minota⁷, ¹Division of Rheumatology and Clinical Immunology, Jichi Medical University, Shimotsuke, Japan, ²Deivision of Rheumatology and Clinical Immunology, Jichi Medical University, Shimotsuke, Japan, ³Department of Orthopaedic Surgery, Orthopedics Clinic Medical Papas, Tochigi, Japan, ⁴Department of orthopedic surgery, Jichi Medical University, Shimotsuke, Japan, ⁵Department of Immunology, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, Japan, ⁶Division of Inflammation Research Center for Molecular Medicine, Jichi Medical University, Shimotsuke, Japan, ⁷Division of Rheumatology and Clinical Immunology, Jichi Medical University, Tochigi, Japan
Background/Purpose: Human monoclonal ACPA (Human-ACPA) is reported to strongly bind to synovium in RA patients [1]. The aims of our study were 1) To investigate…
Abstract Number: 576 • 2016 ACR/ARHP Annual Meeting
Anti-CCP3.1 and Anti-CCP3-IgA Are Elevated in RA-Free Subjects with Idiopathic Pulmonary Fibrosis
Scott Matson¹, Joshua J. Solomon², Jeffrey J. Swigris², Jonathan Chung³, Michael Mahler⁴, Kevin D. Deane⁵ and M. Kristen Demoruelle⁵, ¹Medicine, University of Colorado Denver, Aurora, CO, ²Division of Pulmonary and Critical Care Medicine, National Jewish Health, Denver, CO, ³Radiology, University of Chicago Medical Center, Chicago, IL, ⁴Research and Development, Inova Diagnostics, San Diego, CA, ⁵Rheumatology Division, University of Colorado Denver, Aurora, CO
Background/Purpose: In RA-associated interstitial lung disease (RA-ILD), higher levels of anti-CCP antibodies have been associated with the presence and severity of ILD suggesting a potential…
Abstract Number: 588 • 2016 ACR/ARHP Annual Meeting
Radiographic Progression Is Less Significant in Anti-Carbamylated Antibody-Positive Patients with Rheumatoid Arthritis (RA) Who Were Clinically Active and Under the Treatment with Biological Dmards
Kazuko Shiozawa¹, Ken Tsumiyama² and Shunichi Shiozawa², ¹The Rheumatic Diseases Center, Kohnan Kakogawa Hospital, Kakogawa, Japan, ²Department of Medicine, Rheumatic Diseases Unit, Kyushu University Beppu Hospital, Beppu, Japan
Background/Purpose: A newly discovered anti-carbamylated protein antibody (anti-CarP) is found prior to disease-onset, associates with the conversion towards arthralgia and with a more severe disease…
Abstract Number: 644 • 2016 ACR/ARHP Annual Meeting
Seroprevalence and Its Impact on Radiographic Damage in Korean Rheumatoid Arthritis Patients Starting Biologics
Kichul Shin¹, Seongjun Ha², Inkyung Jung³, Hyoun-Ah Kim⁴ and Shin-Seok Lee⁵, ¹Kyungnam villa #102, Division of Rheumatology, Department of Internal Medicine, SMG-SNU Boramae Medical Center, Seoul, Korea, Republic of, ²Division of Rheumatology, Department of Internal Medicine, SMG-SNU Boramae Medical Center, Seoul, Korea, The Republic of, ³Department of Biostatistics, Yonsei University College of Medicine, Seoul, Korea, The Republic of, ⁴Ajou University Hospital, Suwon, South Korea, ⁵Rheumatology, Chonnam National University Medical School and Hospital, Gwangju, Korea, The Republic of
Background/Purpose: High titers of rheumatoid factor (RF) and anti-cyclic citrullinated peptide antibody (ACCP) are poor prognostic factors for rheumatoid arthritis (RA) patients. Only few studies…
Abstract Number: 1037 • 2016 ACR/ARHP Annual Meeting
Evaluation of 14-3-3η As a Tool for Diagnosis of Early RA in a European Cohort
Monika Hansson¹, Linda Mathsson-Alm², Anthony Marotta³ and Sascha Swiniarski⁴, ¹Rheumatology Unit, Department of Medicine, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden, ²Thermo Fisher Scientific, Uppsala, Sweden, ³Augurex Life Sciences Corp., Vancouver, BC, Canada, ⁴ImmunoDiagnostics Division Thermo Fisher Scientific, Phadia GmbH, Freiburg, Germany
Background/Purpose: Early diagnosis of rheumatoid arthritis (RA) coupled with an effective treatment strategy is a key imperative in the effective management of disease. Anti-citrullinated peptide…
Abstract Number: 1220 • 2016 ACR/ARHP Annual Meeting
Comparison of Healthcare Utilization of Patients with Rheumatoid Arthritis Who Are Anti-Cyclic Citrullinated Peptide Antibody Positive Versus Negative
L Rosenblatt¹, K Price¹, Y Doleh¹, A Szymialis¹, M Eaddy², A Ogbonnaya², H-C Shih² and L Lamerato³, ¹Bristol-Myers Squibb, Princeton, NJ, ²Xcenda, LLC, Palm Harbor, FL, ³Henry Ford Health System, Detroit, MI
Background/Purpose: Anti-cyclic citrullinated peptide (CCP) antibody is a marker used in the diagnosis of RA, and it may be useful in identifying patients who are…
Abstract Number: 1226 • 2016 ACR/ARHP Annual Meeting
Evaluation of the Association Between C-Reactive Protein and Anti-Citrullinated Protein Antibody in Rheumatoid Arthritis: Analysis of Two Clinical Practice Data Sets
E Alemao¹, Z Guo¹, L Burns¹, M Frits², Jonathan Coblyn², Michael Weinblatt² and NA Shadick², ¹Bristol-Myers Squibb, Princeton, NJ, ²Brigham and Women’s Hospital, Boston, MA
Background/Purpose: The association between inflammatory markers such as CRP or ESR and joint damage has been widely established in RA. Autoantibodies such as RF and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].